Q-omics provides the consensus-scored ZNF155 profile across patient tissues and cancer cell-line models. ZNF155 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF155 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ZNF155 RNA expression shows 20,658 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where ZNF155 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF155 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF155 survival associations across molecular data types. ZNF155 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF155 RNA expression–survival associations across cancer types. High ZNF155 expression shows unfavorable associations in LGG, MESO, LUSC and CESC, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF155 RNA expression.
This table summarizes ZNF155 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF155. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF155 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BLCA and CHOL. The THCA box plot shows higher ZNF155 RNA expression in normal versus tumor tissue (log2 FC = −0.605, t-test p < 0.001).
This table shows molecular features associated with ZNF155 in patient tissues and cancer cell lines. In patient samples, ZNF155 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF155 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
